BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Add time:08/07/2019    Source:sciencedirect.com

SummaryDrug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones displaying loss of 18q21 amplicons that harbor BCL2. Further, persister status is generated via adaptive super-enhancer remodeling that reprograms transcription and offers opportunities for overcoming ABT-199 resistance. Notably, pharmacoproteomic and pharmacogenomic screens revealed that persisters are vulnerable to inhibition of the transcriptional machinery and especially to inhibition of cyclin-dependent kinase 7 (CDK7), which is essential for the transcriptional reprogramming that drives and sustains ABT-199 resistance. Thus, transcription-targeting agents offer new approaches to disable drug resistance in B-cell lymphomas.

We also recommend Trading Suppliers and Manufacturers of Direct Blue 199 (cas 12222-04-7). Pls Click Website Link as below: cas 12222-04-7 suppliers

Prev:Decolorization and mineralization of a phthalocyanine dye C.I. Direct Blue 199 (cas 12222-04-7) using UV/H2O2 process
Next:Twisted bilayer blue phosphorene: A direct band gap semiconductor)